Abstract
1066 Background: Nanoparticle albumin-bound (nab) Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this phase II trial, we evaluated a nab-paclitaxel-containing neoadjuvant regimen in patients with operable breast cancer. Methods: Fifty-five women with operable breast cancer without prior treatment were enrolled. All patients were to receive tri-weekly nab-paclitaxel and cyclophsphamide (TRI-ABC) followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) every 3 weeks for 4 cycles. Tri-weekly trastuzumab was administered concomitant with TRI-ABC in HER2-positive (HER2+ or 3+) patients. Primary endpoint was pathologic complete response (pCR; CR) rate in breast cancer tissue and lymph nodes. Secondary endpoints included clinical response, safety, rate of breast conserving surgery and disease-free survival. Results: Fifty-four patients received at least 1 dose of chemotherapy and were included in this analysis. All pati...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call